Up to 14,000 people could benefit from the first treatment for severe alopecia recommended by NICE

“New one-a-day tablet for people with severe hair loss due to alopecia areata recommended by NICE

Thousands of people with severe hair loss due to alopecia areata are set to benefit from a new one-a-day capsule to help treat the condition. Ritlecitinib (also known as Litfulo and made by Pfizer) is recommended by NICE as an option for treating severe alopecia areata in people aged 12 and over.
The treatment, taken as a daily pill at home, works by reducing the enzymes that cause inflammation and subsequent hair loss at the follicle. It is the first treatment for severe alopecia areata recommended by NICE for use on the NHS.
 
Evidence from clinical trials shows that ritlecitinib is more effective than placebo at improving hair regrowth and that response rates continued to improve for people taking ritlecitinib for up to two years.”
 
How Did We Do?
Overall, how was your experience on our website today?
ExcellentGoodFairPoor
Excellent
Good
Fair
Poor
Were you able to find the information you were looking for?
How clear and easy to understand was the information?
Very ClearClearSomewhat UnclearUnclear
Very Clear
Clear
Somewhat Unclear
Unclear
Selected Value: 10
I am visiting as a:

How Did We Do?

Tell us your feedback – it helps us improve our services.